Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc35041508    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways #MMPMID35041508
  • Chen J; Dai L; Kendrick S; Post SR; Qin Z
  • Antimicrob Agents Chemother 2022[Mar]; 66 (3): e0239521 PMID35041508show ga
  • Recently, remdesivir and molnupiravir were approved for treating COVID-19 caused by SARS-CoV-2 infection. However, little is known about the impact of these drugs on other viruses preexisted in COVID-19 patients. Here we report that remdesivir but not molnupiravir induced lytic reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV), two major oncogenic herpesviruses. Remdesivir induced mature virion production from latently infected cells. Mechanistic studies showed that remdesivir induced KSHV and EBV reactivation by regulating several intracellular signaling pathways.
  • |*COVID-19 Drug Treatment[MESH]
  • |*Epstein-Barr Virus Infections[MESH]
  • |*Herpesvirus 8, Human[MESH]
  • |Adenosine Monophosphate/analogs & derivatives[MESH]
  • |Alanine/analogs & derivatives[MESH]
  • |Herpesvirus 4, Human/physiology[MESH]
  • |Humans[MESH]
  • |SARS-CoV-2[MESH]
  • |Signal Transduction[MESH]
  • |Virus Activation[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    e0239521 3.66 2022